Skip to main content

Table 1 Baseline patient profiles

From: Impact of early initiation of renin-angiotensin blockade on renal function and clinical outcomes in patients with hypertensive emergency: a retrospective cohort study

 

Total (n = 49)

RASi(+) (n = 37)

RASi(-) (n = 12)

p value

Age (y/o)

47.2 ± 11.2

46.6 ± 11.8

49.3 ± 9.5

0.435

Male/female, n (male%)

37/12 (75.5%)

28/9 (75.7%)

9/3 (75.0%)

1.0

Systolic BP (mmHg)

222 ± 28

220 ± 26

231 ± 32

0.364

Diastolic BP (mmHg)

142 ± 21

144 ± 22

139 ± 18

0.323

Heart rate (beats/min)

106 ± 19

109 ± 19

99 ± 17

0.081

BMI (kg/m2)

29.5 ± 6.9

29.9 ± 7.4

28.4 ± 5.3

0.675

Previous hypertensive therapy, n (%)

 Aware of hypertension

39 (79.6%)

29 (78.4%)

10 (83.3%)

1.0

 Duration of hypertension

7.6 ± 9.3 (y)

5.7 ± 6.4 (y)

13.2 ± 13.8 (y)

0.127

  No treatment

32 [82.1%]

25 [86.2%]

7 [70.0%]

0.344

  Under treatment

7 [17.9%]

4 [13.8%]

3 [30.0%]

   with RASi

5

3

2

1.0

    CCBs

6

3

3

1.0

    β blockers

1

0

1

0.429

    Diuretics

2

1

1

1.0

Diabetes, n (%)

4 (8.2%)

3 (8.1%)

1 (8.3%)

1.0

Smoking, n (%)

26 (53.1%)

21 (56.8%)

5 (41.7%)

0.508

  1. BP blood pressure, BMI body mass index, RASi renin-angiotensin system inhibitors, CCBs Ca channel blockers